RCAS1 is a promising therapeutic target against cancer: its multifunctional bioactivities and clinical significance

References

• McNeel DG, Eickhoff J, Lee FT et al. Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res.11, 7851–7860 (2005).
   PubMed Web of Science ®Google Scholar
• Chien AJ, IIIi JA, Ko AH et al. A Phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin. Cancer Res.15, 5569–5575 (2009).
   PubMedGoogle Scholar
• Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med.5, 938–942 (1999).
   PubMed Web of Science ®Google Scholar
• Giaginis C, Giagini A, Theocharis S. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): a novel biomarker in the diagnosis and prognosis of human neoplasia. Histol. Histopathol.24, 761–776 (2009).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Nakashima M, Wake N. Receptor-binding cancer antigen expressed on SiSo cells induces apoptosis via ectodomain shedding. Exp. Cell Res.316, 1795–1803 (2010).
   PubMedGoogle Scholar
• Massague J, Pandiella A. Membrane-anchored growth factors. Annu. Rev. Biochem.62, 515–541 (1993).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Sato M, Tsutsumi O et al. Promoter analysis and chromosomal mapping of human EBAG9 gene. Biochem. Biophys. Res. Commun.273, 654–660 (2000).
   PubMedGoogle Scholar
• Tsuchiya F, Ikeda K, Tsutsumi O et al. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem. Biophys. Res. Commun.284, 2–10 (2001).
   PubMedGoogle Scholar
• Okamura Y, Ma Z, Khatlani TS et al. Molecular cloning of canine RCAS1 cDNA. J. Vet. Med. Sci.65, 913–915 (2003).
   PubMedGoogle Scholar
• Okamura Y, Haraguchi T, Morimoto M et al. Expression of a tumor-associated antigen, RCAS1, in canine mammary tumors. J. Vet. Med. Sci.66, 651–658 (2004).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Nakashima M, Wake N. The biological role of unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front. Biosci.13, 1106–1116 (2008).
   PubMedGoogle Scholar
• Nishinakagawa T, Fujii S, Nozaki T et al. Analysis of cell cycle arrest and apoptosis induced by RCAS1. Int. J. Mol. Med.25, 717–722 (2010).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Hirakawa T et al. Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol. Oncol.97, 772–779 (2005).
   PubMed Web of Science ®Google Scholar
• Nakabayashi H, Nakashima M, Hara M et al. Clinico–pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape. Cancer Lett.246, 182–189 (2007).
   PubMedGoogle Scholar
• Fukuda M, Tanaka A, Hamao A, Suzuki S, Kusama K, Sakashita H. Expression of RCAS1 and its function in human squamous cell carcinoma of the oral cavity. Oncol. Rep.12, 259–267 (2004).
   PubMedGoogle Scholar
• Toyoshima T, Nakamura S, Kumamaru W et al. Expression of tumor-associated antigen RCAS1 and its possible involvement in immune evasion in oral squamous cell carcinoma. J. Oral Pathol. Med.35, 361–368 (2006).
   PubMedGoogle Scholar
• Iwasaki T, Nakashima M, Watanabe T et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int. J. Cancer89, 488–493 (2000).
   PubMedGoogle Scholar
• Suzuki T, Inoue S, Kawabata W et al. EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine–immune interactions. Br. J. Cancer85, 1731–1737 (2001).
   PubMedGoogle Scholar
• Tsujitani S, Saito H, Oka S et al. Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma. Dig. Dis. Sci.52, 549–554 (2007).
   PubMedGoogle Scholar
• Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M, Kaibara N. The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer5, 220–227 (2002).
   PubMedGoogle Scholar
• Nakamura Y, Yamazaki K, Oizumi S et al. Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci.95, 260–265 (2004).
   PubMedGoogle Scholar
• Enjoji M, Nakashima M, Nishi H et al. The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. J. Hepatol.36, 786–792 (2002).
   PubMed Web of Science ®Google Scholar
• Okada K, Nakashima M, Komuta K et al. Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Mod. Pathol.16, 679–685 (2003).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Hirakawa T et al. Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol. Oncol.99, 189–198 (2005).
   PubMed Web of Science ®Google Scholar
• Skyldberg B, Salo S, Eriksson E et al. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl Cancer Inst.91, 1882–1887 (1999).
   PubMed Web of Science ®Google Scholar
• Brinkerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res.6, 4823–4830 (2000).
   PubMedGoogle Scholar
• Przybylo JA, Radisky DC. Matrix metalloproteinase-induced epithelial–mesenchymal transition: tumor progression at Snail’s pace. Int. J. Biochem. Cell Biol.39, 1082–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Sonoda K, Miyamoto S, Kobayashi H et al. The level of RCAS1 expression is inversely correlated with the number of vimentin-positive stromal cells in epithelial ovarian cancer. Int. J. Gynecol. Cancer19, 838–843 (2009).
   PubMedGoogle Scholar
• Byun Y, Chen F, Chang R, Trivedi M, Green KJ, Cryns VL. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ.8, 443–450 (2001).
   PubMed Web of Science ®Google Scholar
• Eckes B, Dogic D, Colucci-Guyon E et al. Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J. Cell Sci.111, 1897–1907 (1998).
   PubMed Web of Science ®Google Scholar
• Nieminen M, Henttinen T, Merinen M, Narttila-Ichihara F, Eriksson JE, Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol.8, 156–162 (2006).
   PubMed Web of Science ®Google Scholar
• Sonoda K, Miyamoto S, Yamazaki A et al. Biologic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer110, 1979–1990 (2007).
   PubMedGoogle Scholar
• Liby TA, Spyropoulos P, Lindner HB et al. Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int. J. Cancer130, 532–543 (2011).
   PubMedGoogle Scholar
• Davis GE, Senger DR. Endothelial extracellular matrix. Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res.97, 1093–1107 (2005).
   PubMed Web of Science ®Google Scholar
• Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer77, 1501–1509 (1996).
   PubMedGoogle Scholar
• Izumi Y, Hirata M, Hasuwa H et al. A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J.17, 7260–7272 (1998).
   PubMed Web of Science ®Google Scholar
• Schweitzer R, Shaharabany M, Segar R, Shilo BZ. Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination. Genes Dev.9, 1518–1529 (1995).
   PubMedGoogle Scholar
• Qi H, Rand MD, Wu X et al. Processing of the Notch ligand delta by the metalloprotease kuzbanian. Science238, 91–94 (1999).
   Google Scholar
• Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22–21–1 expression in the uterine cervical squamous neoplasia. Clin. Cancer Res.4, 1517–1520 (1998).
   PubMedGoogle Scholar
• Sonoda K, Kaku T, Hirakawa T et al. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol. Oncol.79, 424–429 (2000).
   PubMedGoogle Scholar
• Razvi K, Sonoda K, Lee YS, Tham KF, Lim FK, Yong EL. A preliminary study of the immunohistochemistry detection of a novel tumour marker, 22–21–1 antigen, in gynaecological cancer specimens. Ann. Acad. Med. Singapore28, 392–394 (1999).
   PubMedGoogle Scholar
• Kubokawa M, Nakashima M, Yao T et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int. J. Oncol.19, 695–700 (2001).
   PubMedGoogle Scholar
• Leelawat K, Watanabe T, Nakajima M, Tujinda S, Suthipintawong C, Leardkamolkarn V. Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J. Clin. Pathol.56, 764–768 (2003).
   PubMedGoogle Scholar
• Ito Y, Yoshida H, Nakano K et al. Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma. Oncology64, 83–89 (2003).
   PubMedGoogle Scholar
• Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer92, 446–451 (2001).
   PubMedGoogle Scholar
• Aoki T, Inoue S, Imamura H et al. EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur. J. Cancer39, 1552–1561 (2003).
   PubMedGoogle Scholar
• Rousseau J, Tetu B, Caron D et al. RCAS1 is associated with ductal breast cancer progression. Biochem. Biophys. Res. Commun.293, 1544–1549 (2002).
   PubMedGoogle Scholar
• Nakakubo Y, Hida Y, Miyamoto M et al. The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett.177, 101–105 (2002).
   PubMedGoogle Scholar
• Kato H, Nakajima M, Masuda N et al. Expression of RCAS1 in esophageal squamous cell carcinoma is associated with a poor prognosis. J. Surg. Oncol.90, 89–94 (2005).
   PubMedGoogle Scholar
• Oshikiri T, Hida Y, Miyamoto M et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br. J. Cancer85, 1922–1927 (2001).
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Hida Y, Miyamoto M et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer99, 418–423 (2002).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Hirakawa T et al. Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br. J. Cancer89, 546–551 (2003).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Hirakawa T et al. Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol. Oncol.103, 924–931 (2006).
   PubMedGoogle Scholar
• Coban S, Ozkan H, Koklu S et al. The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can. J. Gastroenterol.20, 593–596 (2006).
   PubMedGoogle Scholar
• Akashi T, Oimomi H, Nishiyama K et al. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas26, 49–55 (2003).
   PubMedGoogle Scholar
• Giaginis C, Margeli A, Kouraklis G, Zira A, Tsourouflis G, Theocharis S. Diagnostic and prognostic utility of serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) levels in colon cancer patients. Int. J. Biol. Markers24, 70–76 (2009).
   PubMedGoogle Scholar
• Aoe K, Hiraki A, Maeda T et al. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion. Chest126, 1195–1197 (2004).
   PubMedGoogle Scholar
• Aoe K, Hiraki A, Yamazaki K et al. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Int. J. Oncol.29, 65–72 (2006).
   PubMedGoogle Scholar
• Sonoda K, Miyamoto S, Yotsumoto F et al. Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol. Rep.17, 623–628 (2007).
   PubMedGoogle Scholar
• Dutsch-Wicherek M, Wicherek L. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am. J. Reprod. Immunol.59, 266–275 (2008).
   PubMedGoogle Scholar
• Enjoji M, Noguchi K, Watanabe H et al. A novel tumour marker RCAS1 in a case of extramammary Paget’s disease. Clin. Exp. Dermatol.28, 211–213 (2003).
   PubMedGoogle Scholar
• Yoshida Y, Koga K, Watanabe T et al. Potential utility of the tumour marker RCAS1 for monitoring patients with invasive extramammary Paget’s disease. Acta Derm. Venereol.88, 296–297 (2008).
   PubMedGoogle Scholar
• Enjoji M, Yamaguchi K, Nakamuta M et al. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig. Liver Dis.36, 622–627 (2004).
   PubMedGoogle Scholar
• Sonoda K. Novel therapeutic strategies to target RCAS1, which induces apoptosis via ectodomain shedding. Histol. Histopathol.26, 1475–1486 (2011).
   PubMedGoogle Scholar
• Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.6, 327–338 (2009).
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev.15, 188–200 (2001).
   PubMed Web of Science ®Google Scholar
• Ogushi T, Takahashi S, Takeuchi T et al. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res.65, 3700–3706 (2005).
   PubMedGoogle Scholar
• Han Y, Qin W, Huang G. Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation. Cancer Lett.257, 182–190 (2007).
   PubMedGoogle Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med.267, 44–53 (2010).
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW, Chen EX et al. A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res.14, 3450–3455 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer. Cancer116, 1027–1032 (2010).
   PubMed Web of Science ®Google Scholar
• Bolos V, Gasent JM, Lopez-Tarruella S, Grande E. The dual kinase complex FAK–Src as a promising therapeutic target in cancer. Onco. Targets Ther.3, 83–97 (2010).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Schlange T. Targeting ADAMS and ERBBs in lung cancer. Cancer Cell10, 7–11 (2006).
   PubMed Web of Science ®Google Scholar
• Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci.56, 148–153 (2009).
   PubMedGoogle Scholar